Jefferies upgrades CACI International stock rating on growth outlook

Jefferies upgraded CACI to Buy from Hold and raised its price target to $725 from $700, citing high-single-digit organic growth, funded backlog and expected margin expansion of more than 200 basis points to approximately 13%. In fiscal Q1 2027, adjusted EPS was $7.66 versus $6.57 expected, while revenue rose 8.2% year over year to $2.47 billion but missed the $2.52 billion forecast; CACI raised its full-year outlook. Stifel lifted its target to $925, while UBS trimmed its target to $823; both maintained Buy ratings.

Analysis

CACI’s upside case is increasingly an execution-and-mix story, not simply more federal spending: technology-oriented, outcome-based work could support better economics, but only if funded backlog converts to revenue without labor-cost or delivery friction eroding margins. The near-term read-through is mixed: EPS outperformance alongside a revenue miss can signal operating discipline, but it does not by itself validate the growth trajectory. Verify the source of the EPS beat, cash conversion, and organic revenue/backlog conversion before treating it as durable.

The main second-order risk is competitive: if CACI wins higher-value work, peers such as Leidos, Booz Allen Hamilton, and SAIC could face pressure on recompetes and talent costs. Conversely, tighter labor supply or delayed federal awards could impair the whole government-services group. The 13% margin aspiration and cited growth assumptions are forward claims, not established outcomes. Targets in the article vary widely, and its dates, fiscal-period references, and valuation inputs need reconciliation; do not use broker targets as a consensus valuation anchor.

Days: sentiment and estimate revisions may support shares, but much of the quality narrative may already be reflected. Over 1–3 months, guidance delivery and revenue conversion matter more than another target increase. Over 6–18 months, sustained mix improvement could justify relative multiple strength; slippage would expose the stock to multiple compression. No high-conviction outright trade until valuation and earnings details are verified.

Key Decisions for Investors

• Avoid chasing a headline-driven move. Consider a starter long only after confirming the reported price, fiscal-period data, valuation, and that guidance is supported by funded backlog converting into revenue.
• For a relative-value expression, evaluate long CACI versus a basket of Leidos, Booz Allen Hamilton, and SAIC only if comparable valuation and growth data show CACI’s premium is justified; size the position around the risk that federal-award delays hurt the whole group.
• Track organic revenue growth, backlog conversion, cash flow, and progress toward the stated margin trajectory over the next 1–3 months. Reassess the long thesis if growth falls below the cited high-single-digit pace or margins fail to progress.
• Treat the EPS beat cautiously until its components are clear. A beat driven by items that do not repeat, weak cash conversion, or a further revenue shortfall would falsify the operating-leverage thesis and favor reducing exposure.